1981
Current results of the screening program at the division of cancer treatment, national cancer institute
Goldin A, Venditti J, Macdonald J, Muggia F, Henney J, Devita V. Current results of the screening program at the division of cancer treatment, national cancer institute. European Journal Of Cancer 1981, 17: 129-142. PMID: 6894902, DOI: 10.1016/0014-2964(81)90027-x.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteScreening programCancer treatmentClinical trialsCancer InstituteHuman tumorsProspective screening programInadequate clinical trialsCategories of drugsActivity of drugsRenal capsuleClinical testingPanel testingScreening panelNew synthetic compoundsClinical interestNew drugsDrugsSubcutaneous modelTreatmentTumorsAntitumor agentsTrialsPotential usefulnessDefinitive answerAnimal toxicology for early clinical trials with anticancer agents.
Rozencweig M, Von Hoff D, Staquet M, Schein P, Penta J, Goldin A, Muggia F, Freireich E, DeVita V. Animal toxicology for early clinical trials with anticancer agents. American Journal Of Clinical Oncology 1981, 4: 21-8. PMID: 6783332.Peer-Reviewed Original ResearchConceptsPhase I clinical trialEarly clinical trialsClinical trialsOrgan system toxicityStarting doseSystem toxicityChemotherapeutic agentsDose-escalation stepsCommon toxic effectsGastrointestinal intoleranceInitial doseClinical dataEscalation stepsAnimal findingsToxic doseToxic manifestationsIndividual drugsPredictive valueAnimal toxicologyMiceDoseIdentical scheduleLD10Acceptable dosesDogs
1979
Human models of human diseases; breast cancer and the lymphomas
Devita V. Human models of human diseases; breast cancer and the lymphomas. International Journal Of Radiation Oncology • Biology • Physics 1979, 5: 1855-1867. PMID: 393666, DOI: 10.1016/0360-3016(79)90571-6.Peer-Reviewed Original Research
1976
Chemotherapy research nurse.
Hubbard S, Devita V. Chemotherapy research nurse. American Journal Of Nursing 1976, 76: 560-5. PMID: 818899, DOI: 10.2307/3423770.Peer-Reviewed Original Research
1972
THE EFFECT OF CHEMOTHERAPY ON THE GROWTH OF LEUKEMIA L1210 II. PERSISTENCE OF A NITROSOUREA‐INDUCED CHANGE IN THE GROWTH CHARACTERISTICS OF TRANSPLANT GENERATIONS
DeVita V, Bray D, Bostick F, Bagley C. THE EFFECT OF CHEMOTHERAPY ON THE GROWTH OF LEUKEMIA L1210 II. PERSISTENCE OF A NITROSOUREA‐INDUCED CHANGE IN THE GROWTH CHARACTERISTICS OF TRANSPLANT GENERATIONS. Cell Proliferation 1972, 5: 459-466. PMID: 4654583, DOI: 10.1111/j.1365-2184.1972.tb00384.x.Peer-Reviewed Original Research
1971
Effects of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) and its degradation products on progression of L1210 cells through the cell cycle.
Bray D, DeVita V, Adamson R, Oliverio V. Effects of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) and its degradation products on progression of L1210 cells through the cell cycle. Cancer Chemotherapy Reports 1971, 55: 215-20. PMID: 5115843.Peer-Reviewed Original Research
1970
Pentamidine: Clinical pharmacologic correlations in man and mice
Waalkes T, Denham C, DeVita V. Pentamidine: Clinical pharmacologic correlations in man and mice. Clinical Pharmacology & Therapeutics 1970, 11: 505-512. PMID: 5310706, DOI: 10.1002/cpt1970114505.Peer-Reviewed Original ResearchConceptsDiffuse interstitial pneumoniaInterstitial pneumoniaUrinary excretionPlasma levelsPneumocystis cariniiSingle intraperitoneal injectionTypes of pneumoniaDosage scheduleCancer patientsMalignant diseaseRenal abnormalitiesConcomitant useIntraperitoneal injectionIntramuscular administrationOrgan transplantationExcretion patternsPatientsPneumoniaPentamidineExcretionDrugsMenDiseaseMiceCariniiThe physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs.
Vogel C, Denham C, Waalkes T, DeVita V. The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs. Cancer Research 1970, 30: 1651-7. PMID: 5457935.Peer-Reviewed Original ResearchConceptsPhysiological dispositionThe effect of chemotherapy on the growth characteristics and cellular kinetics of leukemia L1210.
Young R, DeVita V. The effect of chemotherapy on the growth characteristics and cellular kinetics of leukemia L1210. Cancer Research 1970, 30: 1789-94. PMID: 5457940.Peer-Reviewed Original Researchhe determination of pentamidine (4,4'-diamidinophenoxypentane) in plasma, urine, and tissues.
Waalkes T, DeVita V. he determination of pentamidine (4,4'-diamidinophenoxypentane) in plasma, urine, and tissues. Translational Research 1970, 75: 871-8. PMID: 5442852.Peer-Reviewed Original Research
1969
Plasma Pyridoxal Phosphate Depletion by the Carcinostatic Procarbazine
Chabner B, DeVita V, Considine N, Oliverio V. Plasma Pyridoxal Phosphate Depletion by the Carcinostatic Procarbazine. Experimental Biology And Medicine 1969, 132: 1119-1122. PMID: 5360989, DOI: 10.3181/00379727-132-34378.Peer-Reviewed Original ResearchThe thymidine-14C and -3H double-labeling technic in the study of the cell cycle of L1210 leukemia ascites tumor in vivo.
Young R, DeVita V, Perry S. The thymidine-14C and -3H double-labeling technic in the study of the cell cycle of L1210 leukemia ascites tumor in vivo. Cancer Research 1969, 29: 1581-4. PMID: 5807231.Peer-Reviewed Original ResearchRelationship of normal CDF1 mouse leukocyte kinetics to growth characteristics of leukemia L1210.
DeVita V, Denham C, Perry S. Relationship of normal CDF1 mouse leukocyte kinetics to growth characteristics of leukemia L1210. Cancer Research 1969, 29: 1067-71. PMID: 5781099.Peer-Reviewed Original Research
1968
Antitumor activity and some pharmacologic properties of anthramycin methyl ether.
Adamson R, Hart L, DeVita V, Oliverio V. Antitumor activity and some pharmacologic properties of anthramycin methyl ether. Cancer Research 1968, 28: 343-7. PMID: 5641523.Peer-Reviewed Original Research
1967
The physiological disposition of the carcinostatic 1,3‐bis(2‐chloroethyU‐l‐nitrosourea (BCNU) in man and animals
DeVita V, Denham C, Davidson J, Oliverio V. The physiological disposition of the carcinostatic 1,3‐bis(2‐chloroethyU‐l‐nitrosourea (BCNU) in man and animals. Clinical Pharmacology & Therapeutics 1967, 8: 566-577. PMID: 4951973, DOI: 10.1002/cpt196784566.Peer-Reviewed Original Research
1964
SOME PHARMACOLOGIC PROPERTIES OF A NEW ANTITUMOR AGENT, N-ISOPROPYL-ALPHA-(2-METHYLHYDRAZINO)-P-TOLUAMIDE, HYDROCHLORIDE (NSC-77213).
OLIVERIO V, DENHAM C, DEVITA V, KELLY M. SOME PHARMACOLOGIC PROPERTIES OF A NEW ANTITUMOR AGENT, N-ISOPROPYL-ALPHA-(2-METHYLHYDRAZINO)-P-TOLUAMIDE, HYDROCHLORIDE (NSC-77213). Cancer Chemotherapy Reports 1964, 42: 1-7. PMID: 14226125.Peer-Reviewed Original Research